| 
April
2004 Testimony to the Labor, Health and Human Services, and Education
Subcommittee of the House Appropriations Committee
By
Marsha A. Martin, D.S.W., Executive Director
AIDS Action
Good
morning Mr. Chairman, and Members of the Committee. I am Dr. Marsha
A. Martin, executive director of AIDS Action. I am pleased to
have the opportunity to address the members of this committee
on the importance of adequate funding for fiscal year 2005 for
the HIV/AIDS portfolio. The federal government’s commitment to
funding research, prevention, and care and treatment for those
living with HIV and AIDS is critical. We would not be where we
are today in responding to this epidemic without the 23-year commitment
of the federal government to fund HIV and AIDS programs.
Our
goals are simple: effective, evidence-based HIV treatment and
prevention services, an unrelenting pursuit for a cure and a vaccine
for HIV infection, and a public health system that ensures that
services are available to all those in need. Our commitment is
clear: AIDS Action is here Until It’s Over.
On
behalf of AIDS Action’s diverse membership of community-based
AIDS service organizations, public health departments, researchers,
educators, and advocates, I would like to share with you some
of the salient issues impacting the funding picture for fiscal
year 2005. AIDS Action, through its member organizations and the
greater public health community, has worked to enhance HIV/AIDS
prevention programs, research protocols, and care and treatment
services; and to secure comprehensive resources to address community
needs. Since 1984, AIDS Action has been committed to this important
work.
Despite the good news of improved treatments for HIV disease,
and longer and healthier lives for many people living with HIV
and AIDS, stark realities remain:
-
There is no cure, and there is no vaccine.
-
There are more people living with HIV and AIDS today than ever
before.
-
Access to health care remains, at best, unequal.
-
Even the best treatments do not work for everyone, and some
have debilitating side-effects.
Yet if we have the will to implement effective, evidence-based
HIV prevention programs, HIV is 100% preventable.
I was fortunate to be at the White House on January 31, 2003,
along with the Presidential Advisory Council on HIV/AIDS, leaders
in the HIV/AIDS advocacy and faith communities, and providers
of services for HIV positive individuals, when President Bush
offered details of the global AIDS plan that he announced in
his January 28th State of the Union address.
We applaud the President’s statement that, “There's no doubt
we can bring hope in all parts of the world, not only in Africa,
but in neighborhoods in our own country where people wonder
what the American Dream means,” but unfortunately, attainment
of the Dream is not being sufficiently supported with the President’s
fiscal year 2005 budget request for the HIV/AIDS portfolio.
It is my hope that the Congress, through the good work of this
subcommittee, will address the true needs of the HIV/AIDS federal
funding portfolio here at home.
Even
before beginning the next fiscal year, providers of HIV/AIDS
services are already working from a deficit. The .59% rescission
that was executed on all non-defense discretionary spending
during the final negotiations for FY 2004 had a devastating
impact on the HIV/AIDS portfolio.
Today, the Ryan White Comprehensive AIDS Resources Emergency
(CARE) Act provides services to more than 533,000 people infected
with and affected by HIV throughout the United States and its
territories. It is the single largest source of federal funding
solely focused on the delivery of HIV/AIDS services and it provides
the framework for our national response to the HIV/AIDS epidemic.
This year, there was an overall increase of 14.5% in the estimated
number of living AIDS cases among the fifty-one hardest hit
eligible metropolitan areas (EMA) in the United States, with
increases as high as 22.6% in some areas. Funds from Title I
of the Ryan White CARE Act, designed to provide services in
these areas, were reduced. Forty of the fifty-one jurisdictions
experienced a decrease in funding, with some decreases as high
as 15%.
-
Seven of the nine EMAs in California (Los Angeles, Oakland,
Orange County, Riverside-San Bernardino, San Diego, San Francisco,
and San Jose) saw an increase of 13.8% in estimated living
AIDS cases, yet lost 8.7% of their funding ($9.3 Million).
-
Two of the three EMAs in New York (Dutchess County and Nassau)
saw an increase of 11.9% in estimated living AIDS cases, yet
lost 8% of their funding ($624,603).
-
Four of the five Texas EMAs (Austin, Dallas, Fort Worth, and
Houston) saw an increase of 14% in estimated living AIDS cases,
yet lost more than 5% of their funding ($2.1 million).
-
Four of the six EMAs in Florida (Jacksonville, Miami, Tampa-St.
Petersburg, and West Palm Beach) saw an increase of 13.1%
in estimated living AIDS cases, yet lost 4.7% of their funding
($2.4 Million).
-
Cleveland, the only EMA in Ohio, saw an increase of 12.7%
in estimated living AIDS cases, yet lost 3% of its funding
($106,767).
-
Philadelphia, the only EMA in Pennsylvania, saw an increase
of 15.2% in estimated living AIDS cases, yet lost 1.2% of
its funding ($295,817).
Some
of the services provided under Title I include physician visits,
laboratory services, case management, home-based and hospice
care, nutrition services, and substance abuse and mental health
services. According to the most recent data available from the
Health Resources and Services Administration (HRSA), more than
half (51.8%) of Title I funds are allocated to core health care
services, and more than one-third (35.0%) are allocated to services
closely associated with medical care (including care coordination
and referral, medically-based housing, and the like). These
services are critical to ensuring patients have access to, and
effectively utilize, life-saving therapies.
Title II of the CARE Act ensures a foundation for services in
each state and territory, including the critically important
AIDS Drug Assistance Program (ADAP) and Emerging Communities
Program. Funding for the Title II base grants (excluding ADAP
and Emerging Communities) decreased from $296,412,000 in FY
2003 to $292,279,000 in FY 2004 for a total decrease of over
$4 million ($4,133,000).
Funding for Emerging Communities remained stable at $10 million,
but it was divided among an increased number of communities.
Of the fifteen states represented by members of this subcommittee,
twelve states received decreases in Title II funding in the
current fiscal year, totaling nearly $3.5 million ($3,429,403).
We applaud the President’s recommended $35 million ($34,999,570)
increase in his FY 2005 budget for the AIDS Drug Assistance
Program. ADAP provides medications for the treatment of individuals
with HIV who do not have access to Medicaid or other health
insurance. According to the National ADAP Monitoring Project,
approximately 80,035 clients received medications through ADAP
in June 2002. In the fifteen states represented by this subcommittee,
54,032 people with HIV were served that month.
A single drug in the multiple-drug regimen of highly active
antiretroviral therapy (HAART)—the standard of care for HIV
disease—may cost as much as $15,000 annually. Drugs to treat
other infections may bring the annual cost for a single HIV
patient to $40,000 a year. With the increased number of people
living with AIDS, a continuing domestic infection rate of 40,000
people per year, and cuts in funding to state Medicaid programs,
funding pressures on ADAP have increased. Over the years, ADAP
has proven to be a remarkable program for allowing people to
receive the care and treatment they need. Consequently, AIDS
Action urges Congress both to fully fund ADAP and to consider
restructuring ADAP to ensure universal access to all needed
drugs, regardless of state of residence. Moreover, many of the
medicines supplied through ADAP reach maximum efficacy only
in conjunction with proper nutrition. Therefore, we urge Congress
to continue funding for Ryan White CARE Act nutrition programs.
The Title III portion of the Ryan White CARE Act is awarded
under the Early Intervention Services program. Grant recipients
include community-based clinics and medical centers, hospitals,
public health departments, and universities in 22 states and
the District of Columbia. The grants are targeted toward new
and emerging sub-populations in the HIV epidemic. The Title
III funds are particularly needed in rural areas where HIV care
and treatment is still relatively new. Urban areas also continue
to need Title III funds to ensure that the emerging populations
are not shortchanged as they struggle to meet the needs of previously
identified HIV positive populations.
The Title IV portion of the Ryan White CARE Act is awarded under
the Comprehensive Family Services Program to provide comprehensive
HIV/AIDS care for women, infants, children, and youth, as well
as their affected families. These grants are utilized to plan
for services that provide overall HIV comprehensive care and
treatment and to strengthen the safety net for HIV positive
individual and their families.
If we are to comprehensively address the HIV care and treatment
crisis in the United States, we must never forget the smaller—but
nonetheless significant—programs in the CARE Act: AIDS Education
and Training Centers (AETC), dental reimbursement, and special
projects of national significance (SPNS). These programs have
been affected by diminished federal funding just as the rest
of the CARE Act titles have. While the President proposes increased
funding and reliance on community health centers nationwide
to provide care to the uninsured and under insured, we are simultaneously
faced with a dearth of knowledge about proper HIV care on the
part of community providers. The role of the AETCs is invaluable
to ensuring that proper education is available to physicians
who are being asked to treat increasing numbers of HIV positive
patients who depend on them for care. Dental care is another
crucial part of the spectrum of services needed by people living
with HIV disease. Oral health is one of the first aspects of
health care to be neglected by those who cannot afford, or do
not have access to, proper medical care. Oral health problems
are often one of the first manifestations of HIV disease. Reimbursement
offered by this CARE Act program allows dental education institutions
to offer their much needed services to people living with HIV.
And finally, in this time of rising infections and strapped
care systems, we need to find more innovative models of care,
which testifies to the importance of the SPNS programs. SPNS
– the research and development arm of the CARE Act – provides
the funding for these models.
AIDS Action believes the entire Ryan White CARE Act portfolio
needs $3.1 billion for FY 2005 to address the true needs of
the 850,000 to 950,000 people that the Centers for Disease Control
and Prevention (CDC) estimates are living with HIV and AIDS
in the United States. President Bush has only requested just
over $2 billion ($2,079,967,030).
HIV continues to be an ongoing public health crisis. Despite
treatment advances, there was a 2% increase in progression of
HIV to AIDS from 2001 to 2002—the first such increase in several
years. AIDS-defining conditions are the leading cause of death
among African-American women between the ages of 25 and 34 and
they are the third leading cause of death among all African
Americans in this age group. It is the sixth leading cause of
death for Latinos and whites in this age group.
According to the CDC’s December 2002 HIV/AIDS Surveillance Report,
886,575 cumulative cases of AIDS have been diagnosed in the
United States, with a total of 501,669 deaths since the beginning
of the epidemic. The CDC also estimates that between 850,000
and 950,000 people are living with HIV and AIDS in the United
States, and approximately one-quarter of them, or 180,000 –
280,000 people, are unaware of their status and could unknowingly
transmit the virus to another person.
For several years, estimates of new infections have remained
at 40,000 per year, compared to an estimated 180,000 new infections
in the mid 1980s: an extraordinary achievement in efforts against
HIV. However, newer estimates suggest that annual infections
may be climbing back up, to as high as 60,000 per year.
To reduce even further the number of new infections, the CDC
implemented a new initiative last April called Advancing HIV
Prevention: New Strategies for a Changing Epidemic (AHP), consisting
of four key strategies:
-
Make HIV testing a routine part of medical care.
-
Implement new models for diagnosing HIV infection outside
medical settings.
-
Prevent new infections by working with persons diagnosed with
HIV and their partners
-
Decrease mother-to-child transmission of HIV.
The Urban Coalition for HIV/AIDS Prevention (UCHAPS), which
represents the six cities that are directly funded by the CDC
and is an AIDS Action board member, has responded positively
to the AHP Initiative. UCHAPS members are working with the CDC
to implement the Initiative effectively in their respective
communities.
This Initiative, however, does not supersede the HIV Prevention
Strategic Plan that was published by the CDC in 2001 and stated
a goal of reducing by half the number of new HIV infections
by 2005. These strategies, though innovative, do require additional
funding for implementation. AIDS Action is concerned that the
President has only requested $1,000,491,000 for fiscal year
2005 for the CDC HIV/AIDS, Sexually Transmitted Disease (STD),
and Tuberculosis (TB) Prevention program. This request is $4,546,000
less than what the CDC received in the current fiscal year.
AIDS Action believes that the CDC HIV/AIDS, STD, and TB Prevention
programs actually need $2 billion to address the true unmet
needs of prevention in HIV/AIDS, STDs, and TB.
How do we continue to strive for the goal of cutting new infections
to 20,000 by 2005 without new resources, new partnerships, and
new funding? It is important to note that funding that is well
spent on successful, prevention programs now will prevent higher
cost dollars associated with the care and treatment of HIV positive
people in the future.
Research on the domestic HIV epidemic is vital to the control
of this disease. Research that includes biomedical, behavioral,
and social services is the cornerstone of HIV prevention research.
The research agenda for HIV prevention science at the Office
of AIDS Research’s (OAR), part of the National Institutes of
Health (NIH) targets interventions to both infected and uninfected
at-risk individuals to reduce HIV transmission. It is essential
that OAR continues its groundbreaking research to secure a vaccine
that will keep HIV negative people negative as well as its research
on treatment vaccines that will help HIV positive people maintain
optimal health. The research on microbicides for vaginal and
anal sexual intercourse is critical as well. The use of microbicides
by the receptive partner will give them power over their personal
health when they cannot negotiate condom use with their partner
to protect themselves from HIV transmission.
The research at NIH on new medications for drug resistant strains
of HIV is also critical. The current success of treatment for
people living with HIV and AIDS is due in large part to early
research investments in new drugs that now have improved the
health of HIV positive individuals. The United States must continue
to take the lead in the research and development of new medicines
to treat current and future strains of HIV. Primary prevention
of new HIV infections must remain a high priority in the field
of research.
Behavioral research to help individuals delay the initiation
of sexual relations, limit the number of sexual partners, limit
the consumption of alcohol and drugs prior to sexual relations,
and move from drug use to drug treatment are all critically
important in finding a solution to the spread of HIV in the
United States. NIH’s Office of AIDS Research is critical in
all of these research arenas. Increased funding is necessary
to ensure the resources that are needed to address all the research
concerns are available both now and in the future. Commitment
in research will ultimately decrease the care and treatment
dollars needed if HIV continues to spread at the current rate.
AIDS Action is concerned that President Bush has only requested
$2.93 billion for the AIDS portfolio at NIH. AIDS Action believes
the National Institutes of Health AIDS portfolio must be funded
at $3.327 billion for fiscal year 2005. We are also concerned
about President Bush’s budget proposal to cut $2.6 billion over
the next five years at NIH in an effort to reduce the federal
budget deficit in half.
On behalf of all Americans living with HIV and AIDS and those
affected by it, AIDS Action asks that you carefully consider
all the ramifications of these domestic cuts to the HIV/AIDS
portfolio, and help us to help others save lives by allocating
sufficient funds to address our challenges.
Respectfully submitted,
Marsha A Martin, Executive Director
AIDS Action
1906 Sunderland Place, NW
Washington, DC 20036
Phone: 202-530-8030
|